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Preface to the psoriatic arthritis supplement
Philip Mease 1,2
Introduction
This supplement of Rheumatology is devoted to the
‘many faces’ of PsA. Highlighted is the point that PsA is
a heterogeneous disease regardless of viewpoint, from
genetics, pathophysiology, clinical features, assessment
of disease activity or treatment. PsA can be likened to
an orchestra performance. At times, the full orchestra—
strings, brass, woodwinds, percussion—is playing,
including arthritis (synovitis), enthesitis, dactylitis, spine
inflammation, skin and nail disease, along with key
comorbidities such as metabolic syndrome and associ-
ated conditions such as uveitis and inflammatory bowel
disease. But at other times, or based on individual pres-
entation, only certain sections or even a single section is
playing, such as the patient who is presenting predom-
inantly with back pain, arthritis, skin disease or enthesi-
tis. On X-ray we can observe different forms of
pathology from digit to digit, with osteolysis in one and
osteoproliferation in the adjacent one. Different immuno-
logic mechanisms may be operative in the spine and
peripheral joints and entheses, or the skin and musculo-
skeletal domains, leading to differences in treatment re-
sponse to targeted therapies in these different parts of
the body. Independent of treatment, the dynamics of the
various orchestra sections may change, at times forte,
at times pianissimo, or not at all. When I am educating
patients at their first presentation, I am able to advise
them about what to expect in broad brush strokes, but I
also advise them that their specific manifestations and
disease course will be unique and unlike that of any
other patient, simply due to the heterogeneity of PsA.
The authors in this supplement provide an up-to-date
review of our current understanding of PsA in genetics,
clinical assessment and treatment recommendations.
PsA genetics
Winchester and FitzGerald review recent studies on the
genetic underpinning of PsA. First, by comparing
patients who have psoriasis with no musculoskeletal
manifestations and those with PsA, it is clear there are
distinctive HLA patterns in one population vs the other.
Within the PsA phenotype, there are subphenotypes that
are also associated with certain HLA patterns. The indi-
vidual patient’s susceptibility alleles determine the T cell
repertoire, which determines what disease phenotype
will become manifest as well as the timing of disease
appearance and also disease severity. For example, the
presence of HLA-B*40:01 and HLA-B*44:01 in psoriasis
patients appears to be protective against the develop-
ment of PsA. Patients with PsA spondylitis who have
HLA-B*08:01 are more likely to present with asymmetric
sacroiliitis, whereas those with HLA-B*27:05:02 are
more likely to have symmetric sacroiliitis, enthesitis and
dactylitis. The authors illustrate a number of such sub-
phenotypes that appear to be directed by genetic speci-
ficity. This work points toward a future when we will be
better able to predict disease evolution, which may aid
us in patient education as well as targeting treatment.
PsA enthesitis (parts 1–3)
The clinical domain of enthesitis has recently become a
special focus of translational and clinical research. Thus
in this supplement, we have devoted three separate but
coordinated articles to the subject: clinical description
and pathophysiology (Araujo and Schett), imaging as-
sessment (Kaeley) and clinical assessment and treat-
ment (Mease). Enthesitis is characterized by
inflammation at the site of tendon, ligament and joint
capsule fiber attachment to bone. The anatomy is com-
plex, involving the morphologic transition from pure ten-
don or ligament fibers to mineralized fibrocartilage to
bone anchoring well below the bone cortex, thus provid-
ing the strength to withstand strong force while still pro-
viding some elasticity of movement. Vascularization
comes from the bone marrow as well as from the extra-
osseous space, which is the source of immune cells and
cytokines that migrate to this anatomic location and, in
addition to resident immune cell reactivity, set up an in-
flammatory response to mechanotrauma, infectious anti-
gens or a distant response to microbiome dysregulation.
Key molecular mediators and cells include PGE2, IL-17,
IL-23, IL-22, TNF and a number of different cell types,
including dendritic cells, TH17 cells, innate lymphoid
cells, cd T cells and others. Animal models suggest that
the enthesium may be one of the first sites of inflamma-
tion noted in SpA pathogenesis. McGonagle has utilized
the term ‘enthesis organ’ to denote the complex
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anatomy and immunology of this site. Postinflammatory
changes can include ossification or enthesophyte
formation.
Kaeley reviews the imaging approaches to enthesitis
evaluation. Because of the limitations of radiography to
evaluate soft tissue and inflammation, the utility of X-ray
is limited. Thus the focus is more on advanced imaging
techniques such as ultrasound and MRI. Advances in
ultrasound technology now allow us to evaluate enthesi-
tis in a granular way, with both anatomic characteriza-
tion, e.g. tendon width, as well as the presence of
active inflammation through the use of power Doppler.
The number of rheumatologists trained in ultrasound has
increased significantly in recent years, allowing the tech-
nique to be utilized readily in the clinic. Multiple enthe-
sial sites can easily be evaluated in a brief encounter,
thus increasing the feasibility of the technique. A limita-
tion is that ultrasound cannot visualize beyond the bone
cortex and thus is not reliable to evaluate osteitis asso-
ciated with enthesitis. On the other hand, MRI is cap-
able of evaluating both the tendon–ligament as well as
the bone aspects of enthesitis, for a more comprehen-
sive view. Both standard MRI and newer technologies
such as dynamic contrast-enhanced MRI can provide
exquisite tissue detail about both inflammation and
structural changes. A disadvantage of standard MRI is
that it stages one body area at a time, which is partially
corrected by improving the quality of whole body MRI.
Mease reviews the performance characteristics of
various enthesitis indices used to measure enthesitis by
physical examination in clinical trials and registries.
These include the Leeds Enthesitis Index (LEI), the
Spondyloarthritis Research Consortium of Canada
(SPARCC) Index and the Maastricht Enthesitis Index
(MASES) that are currently being used. A limitation of
these measures is that they may not always measure
‘itis’ but may instead simply measure ‘algia’, i.e. pain
sensitivity rather than true inflammation. Despite this
limitation, they have generally performed well in discrimi-
nating treatment from placebo in clinical trials. Mease
then proceeds to describe the enthesitis results for each
of the PsA treatments. It is on the basis of these results,
coupled with the presence and impact of enthesitis in
the patient we are working with, that helps guide the
choice and monitoring of therapy. Also reviewed is the
significant impact of enthesitis on function and quality of
life as illuminated in clinical registries. The ability of tar-
geted therapies such as those that inhibit TNF and IL-17
to effect enthesitis remission is one of the striking suc-
cess stories of currently available and emerging
therapies.
PsA assessments
McGagh and Coates review the evolving field of clinical
measurement of PsA, particularly in clinical trials. Prior
to this century there were essentially no validated meas-
ures for the variety of clinical domains that constitute
PsA since there were few therapeutic trials in the
disease. Clinicians typically assumed that medications
that showed efficacy in RA trials would be efficacious in
PsA and medicines benefiting psoriasis would work in
treating PsA skin disease. Similarly, measures for RA,
such as ACR response, an arthritis measure, and the
Psoriasis Area and Severity Index (PASI) were used to
measure those specific domains with reasonable suc-
cess. Indeed, the ACR20 response has generally been
the primary outcome measure for most PsA clinical trials
to date. However, it has been appreciated that these
measures, not designed specifically for PsA, may not
accurately reflect disease in patient’s with an oligoartic-
ular presentation, as well as not measuring other clinical
domains such as enthesitis, which may respond differ-
ently than arthritis or skin disease. Thus a number of
measures have been developed, many of them through
the work of members of the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA), involving both clinical investigators and
patients. These include specific measures of enthesitis,
dactylitis, nail disease and spine symptoms, in addition
to more PsA-specific measures of arthritis. An example
of a more PsA-specific arthritis measure is the Disease
Activity for Psoriatic Arthritis (DAPSA) score. In addition,
a number of patient-reported outcome measures to
measure function, quality of life and fatigue, for ex-
ample, have been either brought in to be used in PsA,
such as the HAQ and 36-item Short Form (SF-36), or
developed specifically for PsA, such as the Psoriatic
Arthritis Impact of Disease (PSAID) questionnaire.
Several composite measures that more holistically take
into account several PsA disease domains, such as
arthritis, skin disease and enthesitis, have been devel-
oped. Examples include the Minimal Disease Activity
(MDA) and Very Low Disease Activity (VLDA) indices,
which are used as targets of therapy, as well as the
Psoriatic Disease Activity Score (PASDAS) and
Composite Psoriatic Disease Activity Index (CPDAI). In
conjunction with OMERACT, the GRAPPA group is cur-
rently methodologically evaluating these measures.
PsA treatment recommendations
Ogdie, Coates and Gladman review the PsA treatment
guidelines published to date, including those from the
GRAPPA and EULAR organizations and the recently pub-
lished ACR–National Psoriasis Foundation guideline.
Thoroughly discussed are the differences and similarities
of each organization’s guideline development process and
the similarities and differences of overarching principles
of treatment and treatment recommendations. Examples
of similarities of overarching principles include shared
decision making with the patient; the importance of
shared management with various medical disciplines de-
pending on the patient’s disease presentation, associated
conditions and comorbidities, including rheumatology,
dermatology, primary care, orthopedics, ophthalmology,
gastroenterology, physical therapy, and so forth; and the
principle of treating to a target of low disease activity or
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remission. The authors describe the process of evaluating
evidence for therapeutic efficacy and safety for a variety
of drugs that have been studied in PsA and then make
recommendations for treatment in various contexts, for
example, in a patient who is just beginning treatment vs a
patient who has experienced various previous treatments,
patients with specific associated conditions or comorbid-
ities that may influence treatment choice, and so on. A
particular challenge in PsA is the multiplicity of clinical
domains that are involved, including arthritis, enthesitis,
dactylitis, spondylitis and skin and nail disease.
Depending on which domains are involved and their rela-
tive severity, treatment recommendations may differ de-
pending on the efficacy of a medicine in those particular
domains. Patient preference for mode of administration
and safety features will play a role in treatment choice as
well. A truism about treatment guidelines, especially for a
disease such as PsA in which the pace of discovery is
rapid and new treatments are being introduced apace, is
that the guidelines are outdated by the time they are pub-
lished, necessitating relatively frequent updates.
PsA patient research partners
Goel reviews a topic that has had historically inadequate
awareness among clinical researchers, the role of
patients not only as subjects of research, or token con-
tributors via focus groups, to qualitative research, but as
completely equal colleagues in the design and conduct
of research projects, as well as being coauthors on pub-
lications and active disseminators of research findings.
The term coined for individuals fulfilling this role is ‘pa-
tient research partner’ (PRP). These are individuals who
may have the disease, or a similar disease, being
researched, but as well the agency to be engaged with
all aspects of research, and in some cases may have a
background of scientific or medical training that can
facilitate their involvement and contribution. Additionally,
an effective PRP will not just represent their own per-
sonal experience with the disease in question, but will
try to represent more broadly the patient experience,
taking into account the ethnic, geographic, gender, age
and sociocultural diversity of the patient population.
Within the rheumatology sphere, PRP engagement
began with the OMERACT 2002 meeting. Since then,
PRPs have become a required fixture of all OMERACT
working groups. An example of the essential role of the
PRP was their ability to highlight the importance of fa-
tigue as a clinical domain of rheumatologic disease,
leading to the inclusion of fatigue as a core item in core
domain sets to be assessed in studies. In addition, nu-
merous research, educational and advocacy organiza-
tions have included PRPs in their framework,
exemplified by the GRAPPA. In addition to a learned re-
view of the evolution of the PRP role in research, Goel
also points out challenges, including ‘tokenism’, i.e. pay-
ing lip service to PRP involvement in order to satisfy
grant requirements, as well as the additional cost
involved in engaging PRPs in research projects.
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